Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial.

Guillaume EberstAmélie AnotaArnaud ScherpereelJulien MazieresJacques MargeryLaurent GreillierClarisse Audigier-ValetteDenis Moro-SibilotOlivier MolinierHervé LénaFrédéric RivièreIsabelle MonnetValérie GounantHenri JanicotRadj GervaisChrystelle LocherEmilie ChartonFranck MorinGérard ZalcmanVirginie Westeelnull null

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

This study demonstrated that adding bevacizumab to standard chemotherapy in patients with advanced MPM had no negative impact on HRQoL. A significant improvement in the peripheral neuropathy and pain HRQoL dimensions was even observed.

Keyphrases

phase iii
clinical trial
open label
phase ii
small cell lung cancer
chronic pain
double blind
placebo controlled
pain management
study protocol
squamous cell carcinoma
locally advanced
advanced non small cell lung cancer
epidermal growth factor receptor